Financial Toxicity
Mr. S did everything he could to beat his cancer. In the end, it was not the cancer but the...
The Hospital’s Eyes
Paul the hospital janitor may appear lowly in the eyes of those who pass him by. However, he keenly observes...
An Evening’s Kiss
Sarah and Evan are on a date and decide to go for a walk. But to find true love, they...
Irony of Measuring Physician Burnout
Physician burnout is finally receiving the recognition it deserves. And in our world of quantitative medicine, we seek to measure...
Peer Reviewed by Social Media
Clinical research and social media have a bizarre relationship, a complex interdependence that we have yet to fully understand. The...
A Matter of Good Faith
The Supreme Court has agreed to clarify the question of good faith as it pertains to physician prescribing behavior. In...
Pandemic Policy Reversals were Predicted
The pandemic has been characterized by poorly conceived policies and their inevitable reversals - with subsequent public outrage. However, these...
Medical Data vs. Medical Necessity
This far into the pandemic, most have become aware of data's influence in deriving policy. But using data to make...
American Individualism, Healthcare Externalities
Individualism has been the defining feature of American culture. Yet, as we enter into a post-pandemic world in which healthcare...
Journalists Decide When COVID-19 Ends
The public's fascination with COVID-19 began with the attention journalists gave to it. But now that public interest in the...
Direct to Consumer Chronic Care Management
Trends in healthcare market forces have predicted new startup business models, including the early success of direct to consumer models...
Of Policies and Uncertainties
The US Preventive Services Task Force recently changed its guidance on aspirin as a preventative medication, a major policy shift....
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more